CN1259051A - 稳定化后的人乳头瘤病毒制剂 - Google Patents

稳定化后的人乳头瘤病毒制剂 Download PDF

Info

Publication number
CN1259051A
CN1259051A CN98805728A CN98805728A CN1259051A CN 1259051 A CN1259051 A CN 1259051A CN 98805728 A CN98805728 A CN 98805728A CN 98805728 A CN98805728 A CN 98805728A CN 1259051 A CN1259051 A CN 1259051A
Authority
CN
China
Prior art keywords
concentration
preparation
seq
hpv
antigen preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN98805728A
Other languages
English (en)
Chinese (zh)
Inventor
G·桑亚尔
D·B·沃尔金
史力
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9709351.2A external-priority patent/GB9709351D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of CN1259051A publication Critical patent/CN1259051A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
CN98805728A 1997-04-08 1998-04-07 稳定化后的人乳头瘤病毒制剂 Pending CN1259051A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4280897P 1997-04-08 1997-04-08
GBGB9709351.2A GB9709351D0 (en) 1997-05-07 1997-05-07 Stabilized human papillomavirus formulations
GB9709351.2 1997-05-07
US60/042,808 2008-04-07

Publications (1)

Publication Number Publication Date
CN1259051A true CN1259051A (zh) 2000-07-05

Family

ID=26311501

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98805728A Pending CN1259051A (zh) 1997-04-08 1998-04-07 稳定化后的人乳头瘤病毒制剂

Country Status (18)

Country Link
EP (1) EP0973546B1 (de)
JP (1) JP4598201B2 (de)
KR (1) KR20010006169A (de)
CN (1) CN1259051A (de)
AT (1) ATE261734T1 (de)
AU (1) AU739829B2 (de)
CA (1) CA2286294A1 (de)
DE (1) DE69822452T2 (de)
DK (1) DK0973546T3 (de)
EE (1) EE9900612A (de)
ES (1) ES2216280T3 (de)
IL (1) IL132201A0 (de)
NO (1) NO994879L (de)
NZ (1) NZ500028A (de)
PL (1) PL336715A1 (de)
PT (1) PT973546E (de)
SK (1) SK138199A3 (de)
WO (1) WO1998044944A2 (de)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102085354A (zh) * 2010-12-30 2011-06-08 重庆大学 一种治疗人乳头瘤病毒16型引发的肿瘤的多肽药物
CN104962567A (zh) * 2013-12-03 2015-10-07 北京康乐卫士生物技术股份有限公司 6型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN106399329A (zh) * 2015-08-12 2017-02-15 北京康乐卫士生物技术股份有限公司 33型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN106701797A (zh) * 2015-08-12 2017-05-24 北京康乐卫士生物技术股份有限公司 31型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN106822883A (zh) * 2010-12-14 2017-06-13 葛兰素史密丝克莱恩生物有限公司 分枝杆菌抗原组合物
CN108201623A (zh) * 2016-12-19 2018-06-26 无锡鑫连鑫生物医药科技有限公司 人乳头瘤病毒重组四价疫苗、其制备方法及其应用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP765398A0 (en) 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
JP4841726B2 (ja) * 1999-02-05 2011-12-21 メルク・シャープ・エンド・ドーム・コーポレイション ヒトパピローマウイルスワクチン製剤
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
DE10137102A1 (de) 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
SG10201502490YA (en) 2006-09-29 2015-05-28 Ligocyte Pharmaceuticals Inc Norovirus vaccine formulations
US10130696B2 (en) 2007-09-18 2018-11-20 Takeda Vaccines, Inc. Method of conferring a protective immune response to norovirus
WO2009092113A2 (en) * 2008-01-19 2009-07-23 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the delivery of vaccines to disrupted epithelium
EA029470B1 (ru) 2011-07-11 2018-03-30 Такеда Вэксинс, Инк. Способ стимулирования формирования защитного иммунитета против норовируса
WO2016038625A2 (en) * 2014-09-11 2016-03-17 Cadila Healthcare Limited Superior human papilloma virus antigens with superior immunological properties and vaccine containing it

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2949031A1 (de) * 1978-12-15 1980-07-17 Sandoz Ag Vakzine
DK0732936T3 (da) * 1993-12-09 2000-09-04 Heinrich Exner Adjuvans til antigener, fremgangsmåde til fremstilling og anvendelse
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106822883A (zh) * 2010-12-14 2017-06-13 葛兰素史密丝克莱恩生物有限公司 分枝杆菌抗原组合物
CN102085354A (zh) * 2010-12-30 2011-06-08 重庆大学 一种治疗人乳头瘤病毒16型引发的肿瘤的多肽药物
CN105177025B (zh) * 2013-12-03 2022-11-01 北京康乐卫士生物技术股份有限公司 18型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN104962567A (zh) * 2013-12-03 2015-10-07 北京康乐卫士生物技术股份有限公司 6型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN105002190A (zh) * 2013-12-03 2015-10-28 北京康乐卫士生物技术股份有限公司 11型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN105039358A (zh) * 2013-12-03 2015-11-11 北京康乐卫士生物技术股份有限公司 58型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN105039359A (zh) * 2013-12-03 2015-11-11 北京康乐卫士生物技术股份有限公司 16型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN105177025A (zh) * 2013-12-03 2015-12-23 北京康乐卫士生物技术股份有限公司 18型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN104962567B (zh) * 2013-12-03 2022-11-08 北京康乐卫士生物技术股份有限公司 6型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN105002190B (zh) * 2013-12-03 2022-11-08 北京康乐卫士生物技术股份有限公司 11型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN106399329A (zh) * 2015-08-12 2017-02-15 北京康乐卫士生物技术股份有限公司 33型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN106701797B (zh) * 2015-08-12 2021-06-15 北京康乐卫士生物技术股份有限公司 31型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN106399329B (zh) * 2015-08-12 2021-06-11 北京康乐卫士生物技术股份有限公司 33型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN106701797A (zh) * 2015-08-12 2017-05-24 北京康乐卫士生物技术股份有限公司 31型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN108201623A (zh) * 2016-12-19 2018-06-26 无锡鑫连鑫生物医药科技有限公司 人乳头瘤病毒重组四价疫苗、其制备方法及其应用

Also Published As

Publication number Publication date
DE69822452D1 (de) 2004-04-22
ATE261734T1 (de) 2004-04-15
JP2001519814A (ja) 2001-10-23
AU6953398A (en) 1998-10-30
NZ500028A (en) 2001-08-31
EE9900612A (et) 2000-08-15
NO994879D0 (no) 1999-10-07
WO1998044944A3 (en) 1998-12-30
PT973546E (pt) 2004-06-30
WO1998044944A2 (en) 1998-10-15
EP0973546A2 (de) 2000-01-26
JP4598201B2 (ja) 2010-12-15
DK0973546T3 (da) 2004-06-28
CA2286294A1 (en) 1998-10-15
ES2216280T3 (es) 2004-10-16
KR20010006169A (ko) 2001-01-26
PL336715A1 (en) 2000-07-03
AU739829B2 (en) 2001-10-18
SK138199A3 (en) 2000-06-12
DE69822452T2 (de) 2006-04-20
EP0973546B1 (de) 2004-03-17
IL132201A0 (en) 2001-03-19
NO994879L (no) 1999-12-07

Similar Documents

Publication Publication Date Title
CN1154732C (zh) 编码人乳头瘤病毒11型l1蛋白的分离和纯化的dna分子
CN1259051A (zh) 稳定化后的人乳头瘤病毒制剂
CN1152935A (zh) 乳头状瘤病毒疫苗
CN1761759A (zh) Hpv31l1在酵母中的优化表达
CN1942583A (zh) Hpv58l1在酵母中的最优化表达
CN1859923A (zh) Hpv 45 l1在酵母中的优化表达
CN1147769A (zh) 含有副流感病毒的、用于预防猪呼吸和生殖疾病的疫苗
CN1018793B (zh) 从重组体宿主产生抑肽酶同系物及其制造方法，表达载体、重组体宿主和药物应用
CN1120352A (zh) 稳定的杀菌/增强通透性蛋白质产物及其药用组合物
CN1037174A (zh) 针对人腺癌抗原的新的重组和嵌合抗体
CN1934131A (zh) Hpv52 l1在酵母中的优化表达
CN1055501C (zh) 重组禽痘病毒,培养被上述病毒感染的细胞以及从上述病毒得到的家禽疫苗
CN1173203A (zh) 纯化的乳头状瘤病毒蛋白
CN85106190A (zh) 乙型肝炎病毒表面抗原的生产
CN1100876C (zh) 编码18型人乳头状瘤病毒的dna
CN101062952A (zh) 由人血清白蛋白和干扰素组成的融合蛋白及其编码基因与应用
CN1705747A (zh) 抗hpv疫苗的载体以及该载体转化的微生物
CN1194991C (zh) 重组弓形虫融合蛋白抗原及其制备方法、应用
CN1737144A (zh) 口蹄疫复合多表位二价核酸疫苗的构建
CN1070685A (zh) 能形成粒子的复合乙型肝炎病毒表面蛋白
CN101050238A (zh) 白喉毒素与gm－csf突变体的融合蛋白及其编码基因与应用
CN1067680A (zh) 减少了宿主糖含量的乙型肝炎病毒表面蛋白
CN1641034A (zh) 破伤风毒素重组抗原制备方法及其应用
US6358744B1 (en) Stabilized human papillomavirus formulations
CN1433430A (zh) 肝炎病毒岗哨病毒ⅰ(svi)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1064042

Country of ref document: HK